血栓心脉宁片联合鼠神经生长因子治疗脑梗死的临床研究
|
摘要
目的研究血栓心脉宁片联合注射用鼠神经生长因子治疗脑梗死的临床疗效。方法选取2017年11月—2018年11月海口市人民医院接收的60例脑梗死患者作为研究对象,采用随机数字表法将患者分为对照组和治疗组,每组各30例。对照组患者肌肉注射注射用鼠神经生长因子,用2mL注射用水溶解,1支/次,1次/d;治疗组患者在对照组的基础上口服血栓心脉宁片,2片/次,3次/d。两组患者连续治疗14 d。观察两组患者的临床疗效,同时比较两组治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分和血清学指标。结果治疗后,治疗组总有效率为93.33%,显著高于对照组的76.67%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者NIHSS评分均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组NIHSS评分显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者超氧化物歧化酶(SOD)水平显著升高,同型半胱氨酸(Hcy)和丙二醛(MDA)水平均显著降低(P<0.05);治疗后,治疗组血清学指标水平显著优于对照组(P<0.05)。结论血栓心脉宁片联合注射用鼠神经生长因子治疗脑梗死具有较好的临床疗效,能够改善患者神经功能和血清学指标水平,具有一定的临床推广应用价值。
Objective To study the clinical efficacy of Xueshuan Xinmaining Tablets combined with Mouse Nerve Growth Factor for injection in treatment of cerebral infarction. Methods Patients(60 cases) with cerebral infarction in Haikou People's Hospital from November 2017 to November 2018 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were im administered with Mouse Nerve Growth Factor for injection, dissolved with 2 mL injection water, 1 tube/time, once daily. Patients in the treatment group were po administered with Xueshuan Xinmaining Tablets on the basis of control group, 2 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the NIHSS score and serological indicator in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 93.33%, which was significantly higher than 76.67% in the control group,and there were differences between two groups(P < 0.05). After treatment, NIHSS scores in two groups were significantly decreased,and the difference was statistically significant in the same group(P < 0.05). After treatment, the NIHSS scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment,SOD was significantly increased, but Hcy and MDA levels were significantly decreased(P < 0.05). After treatment, the serological indicator levels in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Xueshuan Xinmaining Tablets combined with Mouse Nerve Growth Factor for injection has good clinical efficacy in treatment of cerebral infarction, can improve the neurological function and serological indicator levels of patients, which has a certain clinical application value.
Objective To study the clinical efficacy of Xueshuan Xinmaining Tablets combined with Mouse Nerve Growth Factor for injection in treatment of cerebral infarction. Methods Patients(60 cases) with cerebral infarction in Haikou People's Hospital from November 2017 to November 2018 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were im administered with Mouse Nerve Growth Factor for injection, dissolved with 2 mL injection water, 1 tube/time, once daily. Patients in the treatment group were po administered with Xueshuan Xinmaining Tablets on the basis of control group, 2 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the NIHSS score and serological indicator in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 93.33%, which was significantly higher than 76.67% in the control group,and there were differences between two groups(P < 0.05). After treatment, NIHSS scores in two groups were significantly decreased,and the difference was statistically significant in the same group(P < 0.05). After treatment, the NIHSS scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment,SOD was significantly increased, but Hcy and MDA levels were significantly decreased(P < 0.05). After treatment, the serological indicator levels in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Xueshuan Xinmaining Tablets combined with Mouse Nerve Growth Factor for injection has good clinical efficacy in treatment of cerebral infarction, can improve the neurological function and serological indicator levels of patients, which has a certain clinical application value.
引文
[1]刘国权,王四安,梁昌华.基层医院急性脑梗死流行病学特点及预后分析[J].右江医学,2013,41(4):555-556.
[2]张宇,魏广宽,张健丽.疏血通注射液联合注射用鼠神经生长因子治疗急性脑梗死疗效观察[J].中国中医急症,2011,20(4):535,560.
[3]谷巍,毕宝曰,陶金柱,等.鼠神经生长因子对急性脑梗死脑保护的临床观察[J].中国医药导刊,2015,17(4):356-357.
[4]黄常旺,包太成,彭梅.血栓心脉宁片治疗脑梗死的疗效观察[J].现代医药卫生,2010,26(19):2972-2973.
[5]中华医学会全国第四次全国脑血管病学术会议.各类血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380.
[6]王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:391-392.
[7]喻恒,龙崇荣,王亮.血清炎性因子联合NIHSS评分评价急性缺血性卒中患者病情的临床研究[J].中国现代神经疾病杂志,2013,13(9):801-804.
[8]徐耀铭,齐晓飞,王姝瑶,等.急性脑梗死早期进展相关危险因素的临床研究[J].中风与神经疾病杂志,2018,35(6):548-549.
[9]方顕文,唐贤勇,于大林.乐脉颗粒联合鼠神经生长因子治疗脑梗死的临床研究[J].现代药物与临床,2017,32(8):1421-1424.
[10]杨帆,陈俊良,周格知,等.鼠神经生长因子治疗急性脑梗死的临床疗效研究[J].中华全科医学,2018,16(6):903-905.
[11]罗向东,曾宪容,郭富强.血栓心脉宁片对急性脑梗死患者血清Hcy、hs-CRP的影响[J].中西医结合心脑血管病杂志,2011,9(9):1070-1071.
[12]吴秀珍,陈方方.急性脑梗死患者治疗前后血清Hcy、hs-CRP、SOD和MDA检测的临床意义[J].放射免疫学杂志,2012,25(4):388-390.
[13]郭小妹,孙兰青.ACI患者治疗前后血清Hcy、APN、SOD和MDA检测的临床意义[J].放射免疫学杂志,2013,26(2):170-171.
[2]张宇,魏广宽,张健丽.疏血通注射液联合注射用鼠神经生长因子治疗急性脑梗死疗效观察[J].中国中医急症,2011,20(4):535,560.
[3]谷巍,毕宝曰,陶金柱,等.鼠神经生长因子对急性脑梗死脑保护的临床观察[J].中国医药导刊,2015,17(4):356-357.
[4]黄常旺,包太成,彭梅.血栓心脉宁片治疗脑梗死的疗效观察[J].现代医药卫生,2010,26(19):2972-2973.
[5]中华医学会全国第四次全国脑血管病学术会议.各类血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380.
[6]王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:391-392.
[7]喻恒,龙崇荣,王亮.血清炎性因子联合NIHSS评分评价急性缺血性卒中患者病情的临床研究[J].中国现代神经疾病杂志,2013,13(9):801-804.
[8]徐耀铭,齐晓飞,王姝瑶,等.急性脑梗死早期进展相关危险因素的临床研究[J].中风与神经疾病杂志,2018,35(6):548-549.
[9]方顕文,唐贤勇,于大林.乐脉颗粒联合鼠神经生长因子治疗脑梗死的临床研究[J].现代药物与临床,2017,32(8):1421-1424.
[10]杨帆,陈俊良,周格知,等.鼠神经生长因子治疗急性脑梗死的临床疗效研究[J].中华全科医学,2018,16(6):903-905.
[11]罗向东,曾宪容,郭富强.血栓心脉宁片对急性脑梗死患者血清Hcy、hs-CRP的影响[J].中西医结合心脑血管病杂志,2011,9(9):1070-1071.
[12]吴秀珍,陈方方.急性脑梗死患者治疗前后血清Hcy、hs-CRP、SOD和MDA检测的临床意义[J].放射免疫学杂志,2012,25(4):388-390.
[13]郭小妹,孙兰青.ACI患者治疗前后血清Hcy、APN、SOD和MDA检测的临床意义[J].放射免疫学杂志,2013,26(2):170-171.